Trial-Results center  
Clinical trial results database in Heart and vessels Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

cardiovascular prevention - cholesterol lowering intervention - all chronical situations


Related trials

IMPROVE-IT, 2014 - ezetimibe vs control

AIM-HIGH, 2011 - niacin vs placebo (on top statin)

ACCORD lipid, 2010 - fenofibrate vs placebo (on top simvastatine)

SHARP, 2010 - ezetimibe+simvastatin vs placebo

ARBITER-HALTS 6, 2010 - ezetimibe vs niacin

SEARCH, 2010 - simvastatin high dose vs simvastatin

Oxford Niaspan Study, 2009 - niacin vs placebo (on top statin)

Emmerich, 2009 - etofibrate vs placebo

ARBITER 6-HALTS (niacin vs ezetimibe), 2009 - niacin vs ezetimibe

ARBITER 2, 2009 - niacin vs placebo (on top statin)

GISSI-HF rosuvastatine, 2008 - rosuvastatin vs placebo

JUPITER, 2008 - rosuvastatin vs placebo

SANDS, 2008 - aggressive treatment vs standard teatment

Tuttle, 2008 - low fat diet vs mediterranean-style diet

SAGE, 2007 - atorvastatin high dose vs pravastatin

METEOR, 2007 - rosuvastatin vs placebo

Krum, 2007 - rosuvastatin vs placebo

CORONA, 2007 - rosuvastatin vs placebo

Chello et al., 2006 - preoperative atorvastatin vs placebo

ASPEN, 2006 - atorvastatin vs placebo

SPARCL, 2006 - atorvastatin vs placebo

Patti et al., 2006 - preoperative atorvastatin vs placebo

MEGA, 2006 - pravastatin vs control

FIELD, 2005 - fenofibrate vs placebo

WHI low fat, 2005 - diet vs usual diet



See also:

  • All cardiovascular prevention clinical trials
  • All clinical trials of cholesterol lowering intervention
  • All clinical trials of rosuvastatin
    		•  
     METEOR study, 2007 TRC5753 
    [NCT00225589] download pdf: rosuvastatin | cholesterol lowering intervention for cardiovascular prevention

    Treatments

    Studied treatment rosuvastatin 40mg daily
    Control treatment placebo

    Patients

    Patients individuals, with either age (mean, 57 years) as the only coronary heart disease risk factor or a 10-year Framingham risk score of less than 10%, modest CIMT thickening (1.2-<3.5 mm), and elevated LDL cholesterol

    Method and design

    Randomized effectives 702 / 282 (studied vs. control)
    Design Parallel groups
    Blinding double-blind
    Number of centre 61
    Geographic area USA, Europe
    Primary endpoint carotid intima-media thickness


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    All cause death

    1 / 702
         0 / 282
         classic 2,01 [0,03;146,84]

    Cardiovascular death

    0 / 702
         0 / 282
         classic 0,40 [0,00;102,51]

    Coronary death

    0 / 702
         0 / 282
         classic 0,40 [0,00;102,51]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    All cause death 1 / 702 (0,1%) 0 / 282 (0,2%) 0,80 [0,03;23,88]  
    Cardiovascular death 0 / 702 (0,1%) 0 / 282 (0,2%) 0,40 [0,01;20,20]  
    Coronary death 0 / 702 (0,1%) 0 / 282 (0,2%) 0,40 [0,01;20,20]  
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction (for a follow-up of )
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.

    Meta-analysis of all similar trials:

    cholesterol lowering intervention in cardiovascular prevention for all chronical situations



    Reference(s)

    TrialResults-center ID TRC5753
    Trials register # NCT00225589
    Study web site link http://www.cardiosource.com/pops/trialSum.asp?trialID=1556, JAMA 2007;297:1344-53
    • Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Bots ML. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.. JAMA 2007 Mar 28;297:1344-53
      Pubmed | Hubmed | Fulltext

    (c) 2004-2016 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100Heart and vessels